+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Viral Vector Manufacturing Market by Type, Disease, Application, End User - Global Forecast to 2023

  • ID: 4605499
  • Report
  • August 2018
  • Region: Global
  • 149 Pages
  • Markets and Markets
1 of 5
The Global Viral Vector Manufacturing Market is Projected to Reach USD 815.8 Million by 2023 from USD 327.8 Million in 2018, at a CAGR of 20.0%

FEATURED COMPANIES

  • Brammer Bio
  • Cobra Biologics
  • Kaneka Eurogentec
  • Lonza
  • Massbiologics
  • Merck KGaA
  • MORE

The global viral vector manufacturing market is projected to grow at a CAGR of 20.0%.
The viral vector manufacturing market is expected to reach USD 815.8 million by 2023 from an estimated USD 327.8 million in 2018, at a CAGR of 20.0%. The growth of this market is expected to be driven by rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, effectiveness of viral vectors in gene therapy delivery, and ongoing research into viral vector-based gene & cell therapies. On the other hand, the high cost of gene therapies and short shelf-life of viral vectors are likely to restrain the growth of this market to a certain extent.

The genetic disorders segment is expected to grow at the highest rate during the forecast period
By disease, the viral vector manufacturing market is segmented into cancer, genetic disorders, infectious diseases, and other diseases. During the forecast period, the genetic disorders segment is expected to grow at the highest CAGR owing to the accelerated research activities on various genetic disorders such as hemophilia A and B, sickle cell anemia, and Huntington’s disease.

The pharmaceutical and biopharmaceutical companies to hold the largest share of the market
Based on end user, the global viral vector manufacturing market is segmented into pharmaceutical and biopharmaceutical companies and research institutes. The pharmaceutical and biopharmaceutical companies segment is expected to hold the largest share of the market in 2018. The successful launch of viral vector gene therapies and a robust pipeline of such therapies are the key factors contributing to the growth of the pharmaceutical and biopharmaceutical companies segment during the forecast period.

North America is expected to dominate the viral vector manufacturing market in 2018
In 2018, North America is expected to account for the largest share of 64.8% of the global viral vector manufacturing market. Factors such as a large number of regenerative medicine companies (including gene and cell therapy companies), increasing research activities, rising prevalence of target diseases, and availability of funding are supporting the growth of the viral vector manufacturing market in North America.

Break of primary participants was as mentioned below:

  • By Company Type – Tier 1–40%, Tier 2–30% and Tier 3–30%
  • By Designation – C-level–20%, Director Level–40%, Others–40%
  • By Region – North America–50%, Europe–20%, Asia Pacific–20%, RoW–10%

The major players in the global viral vector manufacturing market are Lonza (Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), and Spark Therapeutics (US).

Research Coverage:
The report analyzes the viral vector manufacturing market and aims at estimating the market size and future growth potential of this market based on various aspects such as type, disease, application, end user, and region. The report also includes the competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report
The report will help established firms as well as new entrants/smaller firms gauge the pulse of the market, which in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights on the following pointers:
Market Penetration: Comprehensive information on product portfolios offered by key players in the global viral vector manufacturing market. The report analyzes the global viral vector manufacturing market by type, disease, application, end user, and region
Product Innovation: Detailed insights on upcoming trends and product launches in the global viral vector manufacturing market
Market Development: Comprehensive information about the lucrative emerging markets by type, disease, application, and end user
Market Diversification: Exhaustive information about new products, growing geographies, recent developments, and investments in the market
Competitive Assessment: In-depth assessment of market shares and growth strategies of leading players in the global market

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Brammer Bio
  • Cobra Biologics
  • Kaneka Eurogentec
  • Lonza
  • Massbiologics
  • Merck KGaA
  • MORE

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered for the Study
1.3 Currency
1.4 Stakeholders

2 Research Methodology
2.1 Primary Data
2.1.1 Key Data From Primary Sources
2.1.2 Key Industry Insights
2.2 Secondary Data
2.2.1 Key Data From Secondary Sources
2.3 Market Size Estimation
2.4 Market Breakdown and Data Triangulation
2.5 Assumptions for the Study

3 Executive Summary

4 Premium Insights
4.1 Market Overview

5 Market Overview
5.1 Introduction
5.2 Evolution
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Rising Prevalence of Genetic Disorders, Cancer, and Infectious Diseases
5.3.1.2 Availability of Funding for the Development of Gene Therapy
5.3.1.3 Effectiveness of Viral Vectors
5.3.1.4 Ongoing Research Into Viral Vector-Based Gene and Cell Therapies
5.3.2 Restraints
5.3.2.1 High Costs Associated With Gene Therapy
5.3.2.2 Short Shelf-Life of Viral Vectors
5.3.3 Challenges
5.3.3.1 Risk of Mutagenesis and Other Unwanted Outcomes

6 Viral Vector Manufacturing Market, By Type
6.1 Introduction
6.2 Retroviral Vectors
6.2.1 Lentiviral Vectors
6.2.2 Gamma-Retroviral Vectors
6.3 Adenoviral Vectors
6.4 Adeno-Associated Viral Vectors
6.5 Other Viral Vectors

7 Viral Vector Manufacturing Market, By Disease
7.1 Introduction
7.2 Cancer
7.3 Genetic Disorders
7.4 Infectious Diseases
7.5 Other Diseases

8 Viral Vector Manufacturing Market, By Application
8.1 Introduction
8.2 Gene Therapy
8.3 Vaccinology

9 Viral Vector Manufacturing Market, By End User
9.1 Introduction
9.2 Pharmaceutical and Biopharmaceutical Companies
9.3 Research Institutes

10 Viral Vector Manufacturing Market, By Region
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia Pacific
10.5 Rest of the World

11 Competitive Landscape
11.1 Overview
11.1.1 Product Approval
11.1.2 Collaborations, Partnerships, and Agreements
11.1.3 Acquisitions and Mergers
11.1.4 Expansions

12 Company Profiles
12.1 Lonza
12.2 Merck KGaA
12.3 Oxford Biomedica
12.4 Cobra Biologics
12.5 Novasep
12.6 Spark Therapeutics
12.7 Kaneka Eurogentec
12.8 Finvector Vision Therapies
12.9 Brammer Bio
12.10 Cell and Gene Therapy Catapult (CGT Catapult)
12.11 Fujifilm Holdings Corporation
12.12 Uniqure
12.13 Regenxbio
12.14 Massbiologics

13 Appendix
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Subscription Portal
13.4 Introducing RT: Real-Time Market Intelligence
13.5 Available Customizations
13.6 Related Reports
13.7 Author Details

List of Tables (50 Tables)

Table 1 Approved Viral Vector Gene Therapies
Table 2 Number of Clinical Trials Registered on Various Viral Vectors Globally
Table 3 Viral Vector Manufacturing Market, By Type, 2016–2023 (USD Million)
Table 4 Market for Retroviral Vectors, By Type, 2016–2023 (USD Million)
Table 5 Market for Retroviral Vectors, By Region, 2016–2023 (USD Million)
Table 6 Market for Lentiviral Vectors, By Region, 2016–2023 (USD Million)
Table 7 Viral Vector Manufacturing Market for Gamma-Retroviral Vectors, By Region, 2016–2023 (USD Million)
Table 8 Market for Adenoviral Vectors, By Region, 2016–2023 (USD Million)
Table 9 Viral Vector Manufacturing Market for Adeno-Associated Viral Vectors, By Region, 2016–2023 (USD Million)
Table 10 Gene Therapy Applications of Other Viral Vectors
Table 11 Market for Other Viral Vectors, By Region, 2016–2023 (USD Million)
Table 12 Viral Vector Manufacturing Market, By Disease, 2016–2023 (USD Million)
Table 13 Market for Cancer, By Region, 2016–2023 (USD Million)
Table 14 Phase Iii/Iv Clinical Trials Based on Monogenic Diseases
Table 15 Market for Genetic Disorders, By Region, 2016–2023 (USD Million)
Table 16 Viral Vector Manufacturing Market for Infectious Diseases, By Region, 2016–2023 (USD Million)
Table 17 Market for Other Diseases, By Region, 2016–2023 (USD Million)
Table 18 Viral Vector Manufacturing Market, By Application, 2016–2023 (USD Million)
Table 19 Market for Gene Therapy, By Region, 2016–2023 (USD Million)
Table 20 Viral Vector Vaccines Pipeline
Table 21 Viral Vector Manufacturing Market for Vaccinology, By Region, 2016–2023 (USD Million)
Table 22 Market, By End User, 2016–2023 (USD Million)
Table 23 Market for Pharmaceutical and Biopharmaceutical Companies, By Region, 2016–2023 (USD Million)
Table 24 Viral Vector Manufacturing Market Size for Academic Research Institutes, By Region, 2016–2023 (USD Million)
Table 25 Market, By Region, 2016–2023 (USD Million)
Table 26 North America: Market, By Type, 2016–2023 (USD Million)
Table 27 North America: Market for Retroviral Vectors, By Type, 2016–2023 (USD Million)
Table 28 North America: Viral Vector Manufacturing Market, By Disease, 2016–2023 (USD Million)
Table 29 North America: Market, By Application, 2016–2023 (USD Million)
Table 30 North America: Viral Vector Manufacturing Market, By End User, 2016–2023 (USD Million)
Table 31 Europe: Market, By Type, 2016–2023 (USD Million)
Table 32 Europe: Viral Vector Manufacturing Market for Retroviral Vectors, By Type, 2016–2023 (USD Million)
Table 33 Europe: Market, By Disease, 2016–2023 (USD Million)
Table 34 Europe: Viral Vector Manufacturing Market, By Application, 2016–2023 (USD Million)
Table 35 Europe: Market, By End User, 2016–2023 (USD Million)
Table 36 APAC: Viral Vector Manufacturing Market, By Type, 2016–2023 (USD Million)
Table 37 APAC: Market for Retroviral Vectors, By Type, 2016–2023 (USD Million)
Table 38 APAC: Market, By Disease, 2016–2023 (USD Million)
Table 39 APAC: Viral Vector Manufacturing Market, By Application, 2016–2023 (USD Million)
Table 40 APAC: Market, By End User, 2016–2023 (USD Million)
Table 41 RoW: Viral Vector Manufacturing Market, By Type, 2016–2023 (USD Million)
Table 42 RoW: Market for Retroviral Vectors, By Type, 2016–2023 (USD Million)
Table 43 RoW: Market, By Disease, 2016–2023 (USD Million)
Table 44 RoW: Market, By Application, 2016–2023 (USD Million)
Table 45 RoW: Market, By End User, 2016–2023 (USD Million)
Table 46 Rank of Companies in the Global Viral Vector Market, 2018
Table 47 New Approval , 2015–2018
Table 48 Agreements, Partnerships and Collaborations, 2015–2018
Table 49 Acquisitions 2015-2018
Table 50 Expansions, 2015–2018

List of Figures (22 Figures)

Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Data Triangulation
Figure 6 Retroviral Vectors Dominate the Vira Vectors Manufacturing Market
Figure 7 Geographical Snapshot: High Growth Expected in Emerging APAC Markets During the Forecast Period
Figure 8 Accelerated Research Activities in Gene Therapy Drive the Market
Figure 9 Cancer to Dominate the Viral Vectors Manufacturing Market By Disease (2018)
Figure 10 Timeline for Major Events in Gene Therapy
Figure 11 Viral Vectors Manufacturing Market: Drivers, Restraints, and Challenges
Figure 12 Adeno-Associated Viral Vectors: Targeted Therapies
Figure 13 Gene Therapy Research Targets
Figure 14 Number of Gene Therapies in Various Clinical Trial Phases
Figure 15 Lonza: Company Snapshot
Figure 16 Merck KGaA: Company Snapshot
Figure 17 Oxford Biomedica: Company Snapshot
Figure 18 Spark Therapeutics: Company Snapshot
Figure 19 Kaneka Corporation: Company Snapshot (2017)
Figure 20 Fujifilm Holdings Corporation: Company Snapshot (2017)
Figure 21 Uniqure: Company Snapshot (2017)
Figure 22 Regenxbio: Company Snapshot (2017)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
5 of 5
  • Brammer Bio
  • Cell and Gene Therapy Catapult (CGT Catapult)
  • Cobra Biologics
  • Finvector Vision Therapies
  • Fujifilm Holdings Corporation
  • Kaneka Eurogentec
  • Lonza
  • Massbiologics
  • Merck KGaA
  • Novasep
  • Oxford Biomedica
  • Regenxbio
  • Spark Therapeutics
  • Uniqure
Note: Product cover images may vary from those shown
Adroll
adroll